AskBio, a 100% Bayer-owned gene therapy company, has announced that the first participants have been randomized in its Phase II clinical trial in Parkinson's disease (PD) patients.
Recruitment therefore continues in the US for the REGENERATE-PD clinical trial of the investigational gene therapy AB-1005 for the treatment of moderate-stage Parkinson's disease.
Phase Ib data at 36 months demonstrated a favorable safety profile and continued positive trends in the clinical measures assessed of AB-1005 with no associated serious adverse events.
' 'The randomization of the first participants to REGENERATE-PD is good news for people with Parkinson's disease and the physicians who treat them,' said Dr Rajesh Pahwa, Director of the Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, USA, and principal investigator of REGENERATE-PD.
' There is a significant need for neurorestorative therapies for Parkinson's disease, and seeing an important investigational gene therapy progress through a Phase II clinical trial gives hope to patients and the medical community alike. '
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.6%);
- other (0.7%).
Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
